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Despite advances in surgical techniques and clinical regimens,
malignant gliomas usually progress or recur after treatment. It
is widely acknowledged that significant challenges remain in assessing response to treatment of glioma in the time frame in
which response and progression occur. Currently, visual inspection of imaging data is the mainstay to monitor glioma progression; however, this approach may not be accurate or refined
enough to monitor treatment response or evolving prognostic
subtypes. Imaging data have limited ability to distinguish (1)
gliomas from other tumors (eg, primary central nervous system
[CNS] lymphoma), (2) progression from pseudoprogression
resulting from therapy, or (3) minimal or remnant tumoral
burden.1 In addition, imaging is limited by its availability and
feasibility for some patients. This hampers efforts to assess the
response to standard treatment as well as to novel agents and
therefore to manage patients appropriately. More importantly,
it leaves patients with significant uncertainty, sometimes for
many weeks. Developments in imaging technology and application of more advanced assessment of standard data through application of Artificial Intelligence (AI) and machine learning are
moving rapidly but there remains no validated imaging-based
approach to read out response to standard treatment that outperforms standard MRI.2 In addition, among nonenhancing tumors, imaging cannot discriminate between tumor, edema, and
postradiation effect or scarring on T2/FLAIR.
Earlier diagnosis is also a significant unmet need in gliomas,
which to date have not proven amenable to any screening
approach, which is hampered by the relative rarity of the diagnosis as well as the usually nonspecific presenting symptoms.3 The assumption that earlier diagnoses can be made
and that this would lead to better outcomes has therefore not
been addressed in the field. An ideal screening blood-based
biomarker would identify early stage disease, and/or select
patients for specific, personalized therapies and/or monitor response thereby contributing to development of new treatment
approaches.
Accurate diagnosis through a simple blood test will allow
clinicians to detect the evolution of the disease in real time,

thus identifying high-risk patients who may benefit from more
aggressive therapy at an earlier point when intervention could
be more effective. Blood-based biomarkers have been used
routinely for many years in some cancers including prostate
and ovarian cancer and are applied routinely in hematological malignancies to monitor disease burden and detect recurrence. In the era of precision medicine, predictive blood-based
biomarkers have also been applied successfully in several
tumor types, most notably nonsmall cell lung cancer, where
sequential sampling of circulating tumor DNA allows detection of relevant targetable mutations as well as appearance
of resistance mechanisms, for example to epidermal growth
factor receptor (EFGR) targeting agents.4 Across solid tumors,
sampling tumor biology from blood or other relevant body
fluid has been achieved using a wide range of assays and technologies. Some of these approaches, including isolation of
circulating tumor cells (CTCs), have the additional advantage
of permitting read out of RNA and protein levels and application of functional assays as well as monitoring mutational
profile. Other approaches include isolation of tumor-derived
exosomes, reflecting cancer-derived trafficking of genetic material, proteins and lipid and which have the advantage of relatively long half-life compared to ctDNA.5
The promise of all of these approaches is a real-time read
out of tumor status or response without the need to access tumor directly which is particularly appealing in brain
tumor patients. An ideal biomarker for response assessment has been recently described by Jones et al., showing
a rapid sustained nadir that reflects response to treatment
and a sensitive rise that signals relapse early.6 This would
permit treatment when disease is at lowest possible volume,
very likely ahead of clinical symptoms an approach that is
currently being validated in early breast cancer based on
measurement of circulating tumor DNA to monitor relapse.7
An additional advantage in the setting of novel agent treatments is that response as well as early relapse could also be
measured. This is exemplified by the approach being tested
in the ongoing CACTUS study in BRAFmut melanoma where
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monitoring, and surveillance and new agent evaluation, so
different approaches likely need to be combined. This will
require new, collaborative approaches to study design and
assessment.
It also needs to be recognized that some of the most
promising assays may rely on technology that is developing rapidly and may not yet be widely available,
meaning that roll out and timing can be problematic.20 This
may also raise issues about equitable access across regions, jurisdictions, and funding models.
Finally, it should be appreciated that blood-based testing
for disease evaluation will be unfamiliar to our patient
groups and that we therefore need to engage with them
as a community to ensure literacy and buy-in to test these
new approaches within clinical studies and beyond.
To address some of these challenges, the “Brain-Liquid
Biopsy consortium” was established in 2020 as a group of
researchers and clinicians with a shared interest in translating the advances in biomarker technology development
into clinical advances in the field of neuro oncology. The
mission of the consortium is to “accelerate research and
translation of liquid biopsy approaches for brain tumour patients and to support sharing of data and of relevant tissue
resources with the ultimate aim to identify liquid biopsy
techniques that are relevant in real world clinical settings
to improve diagnosis and monitoring for brain tumour
patients.” Participants with a shared interest are encouraged to join. Plans for the consortium include (1) linking
investigators with relevant expertise to those with relevant
tissue, (2) sharing of standard operating procedures across
a variety of different approaches as described above, (3)
encouraging collaborations and connecting members to
industry to expedite bringing technology to consumers,
and (4) providing support for researchers applying for federal and philanthropic support. Since inception the consortium has grown to include 45 members from 10 countries.
Activities to date include a series of webinars, workshops,
and meetings to encourage expertise and resource sharing
and to link discovery science to relevant clinical study
teams. Consortium members worked with the Society for
Neuro Oncology administration to run consecutive education days during the 2020 and 2021 annual meeting on the
topic of tissue and liquid biomarker research. The consortium also has links to industry and other relevant academic
and translational groups including the Focused Ultrasound
Foundation and Blood Pac. Inclusion of statistical and clinical expertise with links to national efforts to collect relevant samples routinely from glioma patients, for example
through the UK Brain Matrix study is an important component of the consortium’s strengths (https://clinicaltrials.
gov/NCT04274283), alongside involvement of partners
with experience of development of liquid biomarkers
through to approval in other settings. We believe this consortium is well suited to support and encourage collaborations with principal investigators involved in clinical trials
by sharing data and findings with consortium members.
A liquid biopsy approach has the ability to monitor and
survey tumor progression after initial treatment. Those patients on specific clinical trials could have their liquid biopsy taken pre- and post-treatment to determine the effect
of the trial compared to standard treatment. An example of
how liquid biopsy can detect differences between standard
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repeated testing of a small gene panel is being used to assess response to BRAF inhibition and support treatment
switching to immunotherapy agents (https://clinicaltrials.
gov/ct2/show/NCT03808441). Liquid biopsies applied in
this way could also have a major impact on study design
since it would significantly enhance our ability to compare approaches rapidly in platform studies with many
parallel arms and potentially select patients for specific
treatments, as is being done in the early phase TARGET
study in metastatic and recurrent solid tumors.8
In the context of glioma, a large range of assays and
technologies have been investigated to date. It is clear that
compared to other solid tumors, CNS tumors release less
tumor material into the systemic circulation, presumably
due to the presence of the blood–brain barrier. Whilst cerebrospinal fluid (CSF) appears to be a better source of
tumor-derived material, repeated sampling is less practical
if the ultimate goal is to fine-tune treatment in real time.9
One interesting approach to address this may be to make
use of blood–brain barrier opening approaches including
focused ultrasound to increase shedding and sensitivity,10
but then again it does not offer the best utility if the aim
is to access recurrence in real time. The well-described
issue of tumor heterogeneity in many CNS tumors, particularly low- and high-grade gliomas also adds complexity
to any tumor-derived sampling including liquid biopsy.11
Nevertheless, although the rarity of tumor-derived material, especially CTC in glioma seems to limit their applicability in this context, early data suggest that several other
liquid biopsy approaches may hold promise including
tumor educated platelets, ctDNA, and exosomes,12–14 as
well as serum spectroscopy.15 We encourage the reader to
review the companion papers in this edition to learn more
about tumor educated platelets, ctDNA, and exosomes.
Recent data also suggest that methylome analysis of cellfree DNA may be particularly powerful as it can identify
cancer-specific large-scale epigenetic aberrations as well
as cancer-specific immune signatures, which increases
sensitivity of detection and may lend itself to a screening
approach.16,17 A comprehensive review of noninvasive
methylation markers in gliomas is discussed in the article by Noushmehr et al. within the same issue.18 Other
approaches to enhance sensitivity include application of
fragmentomics as an initial screen of blood or CSF-derived
tumor DNA.19
Whilst we are entering an era in which one or several
of these promising approaches may soon be clinically applicable, significant challenges still lie ahead. There is a
pressing need for data from prospective clinical studies,
requiring a close interaction with appropriate clinical
study teams. Once the assay technology is optimized the
pathway from discovery science to clinical implementation is also complex, including standardization, analytical statistical methods, and validation between labs and
across diagnoses as well as time and resource intensive
authorization steps. The field therefore needs to prioritize the most promising approaches to focus efforts in the
short and medium term and to work with relevant stakeholders including industry, where diagnostic companies
and drug developers have been quick to enter this space.
It also seems unlikely that one assay will fulfill all the requirements and unmet needs for early diagnosis, disease
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vs trial treatment was recently described by Sabedot et al.17
They provided three such examples each highlighting dramatic changes in their GeLB score as a response to a specific trial treatment. Investigators of clinical trials or those
planning trials should reach out to the consortium for further guidance on how we may synergize efforts.
In summary, the detection of a validated blood basedspecific markers through a noninvasive approach, such
as liquid biopsy, will not only enable clinical neurooncologists the opportunity to assess treatment response
in real time and monitor impending disease progression
and recurrence, but also identify actionable molecular targets to better stratify patients to the appropriate clinical
trials. The prospective assessment of liquid biopsy will also
aid in determining the best treatment course during clinical follow-up of one of the most aggressive human cancers to date. At the moment, we cannot recommend the
best approach to detect and monitor progression, however, we believe that the approaches with the highest potential would be the ones that are cost-effective, where the
liquid biopsy sample is easily attainable (eg, simple blood
draw, urine, or saliva), and for which the approach can
demonstrate high accuracy (ie, at or near 100%). Coupled
with advances in tissue biomarkers and advances in largescale integrative “omics” data as well as novel machine
learning methods emerge, it is clear that noninvasive detection and monitoring of gliomas and other CNS diseases
offers exciting new treatment opportunities that can lead
to improved quality of life for our patients.
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